Table 1. Clinical characteristics of patients in the treated and the untreated group.
| Untreated group, n (%) | Treated group, n (%) | |
|---|---|---|
| All patients | 11 (100) | 30 (100) |
| Age* | ||
| ≥45 years | 5 (45) | 11 (37) |
| <45 years | 6 (55) | 19 (63) |
| Sex | ||
| Male | 8 (73) | 18 (60) |
| Female | 3 (27) | 12 (40) |
| Histologic subtype | ||
| Nodular sclerosis | 6 (55) | 22 (73) |
| Mixed cellularity | 5 (45) | 8 (27) |
| Stage** | ||
| IA-IIA | 5 (45) | 11 (37) |
| IIB-IVB | 6 (55) | 17 (57) |
| Missing | 0 (0) | 2 (6) |
| Primary treatment received | ||
| Radiotherapy only | § | 3 (10) |
| 2–4 ABVD or MOPP/A(B)VD + RT | § | 5 (17) |
| 6–8 ABVD or MOPP/A(B)VD ± RT | § | 10 (33) |
| 6–8 BEACOPP | § | 3 (10) |
| Other*** | § | 7 (23) |
| Missing | § | 2 (7) |
| Autologous stem cell transplantation at relapse | ||
| Yes | § | 14 |
| No | § | 12 |
| Missing | § | 4 |
*Age at diagnosis of relapse in the treated group, and age at primary diagnosis in the untreated group.
**Stage at primary diagnosis.
***Other chemotherapy regimens were: OEPA (3 children and 1 elderly), one patient each received VACOP-B, Bendamustine and CHOP.
§Not applicable.
ABVD = Doxorubicine, Bleomycin, Vinblastine, Dacarbazine, BEACOPP = Bleomycin, Etoposide, Doxorubicine, Cyclophosphamide, Vincristine, Procarbazine, Prednisolone, CHOP = Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone, MOPP = Mustargen, Oncovin, Procarbazine, Prednisolone, OEPA = Oncovin, Etoposide, Prednisolone, Doxorubicine, VACOP-B = Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Prednisolone, Bleomycin